BioScrip Inc. (BIOS)

[ClayTrader]

* * $BIOS Video Chart 01-03-17 * *

Link to Video - click here to watch the technical chart video

[pj McMulligan]

BIOS technical pincher formation divergence

[DEADSKY]

Got a starter;)

[ClayTrader]

* * $BIOS Video Chart 11-08-16 * *

Link to Video - click here to watch the technical chart video

[BillBadaass]

Ugly Ugly Ugly is there any hope?

[willlbone]

Another bad new 8k. More words, more selling.

[Wildbilly]

BIOS breakout and continuation?

Could use more volume.

[stocktrademan]

BIOS bullish 2.96



normal chart


log chart

[Wildbilly]

Joint filing Agreement SC 13G, EX 99.1


North Tide Capital Master, LP – 7,2000,000 - 6.3%

North Tide Capital, LLC – 8,500,000 shares – 7.5%

Conan Laughlin – 8,500,000 - 7.5%

https://www.sec.gov/Archives/edgar/data/1014739/000092963816001520/0000929638-16-001520-index.htm

[willlbone]

Bad news 8k. Many words, probably dilution.

[stocktrademan]

$BIOS recent news/filings

bullish 2.23

## source: finance.yahoo.com

$BIOS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$BIOS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/BIOS/company-info
Ticker: $BIOS
OTC Market Place: Not Available
CIK code: 0001014739
Company name: BioScrip, Inc.
Incorporated In: DE, USA

$BIOS share structure

## source: otcmarkets.com

Market Value: $137,535,226 a/o Mar 17, 2016
Shares Outstanding: 68,767,613 a/o Feb 29, 2016
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.0001

$BIOS extra dd links

Company name: BioScrip, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=BIOS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=BIOS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=BIOS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/BIOS/news - http://finance.yahoo.com/q/h?s=BIOS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/BIOS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/BIOS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=BIOS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/BIOS
DTCC (dtcc.com): http://search2.dtcc.com/?q=BioScrip%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=BioScrip%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=BioScrip%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/BIOS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001014739&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/BIOS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/BIOS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=BIOS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=BIOS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/BIOS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=BIOS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=BIOS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=BIOS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=BIOS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=BIOS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/BIOS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=BIOS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/BIOS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=BIOS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/BIOS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/BIOS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/BIOS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/BIOS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/BIOS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=BIOS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=BIOS



$BIOS DD Notes ~ http://www.ddnotesmaker.com/BIOS

[Enterprising Investor]

BioScrip Provides Business Update on Implementation of Financial Improvement Plan and Progress to Enhance Shareholder Value (1/19/16)

Review of Strategic Alternatives Continues

Patient Census Growth Continues, Cost Savings Initiatives on Track and Increased Cash Collections

ELMSFORD, N.Y., Jan. 19, 2016 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company") today provided an update on the Company's progress implementing its Financial Improvement Plan to enhance shareholder value, improve financial flexibility and position BioScrip for success in 2016. As previously announced, the Company expects the Financial Improvement Plan to realize $35 million - $40 million in annualized net cost savings.

As the Company stated in its third quarter 2015 financial results in November 2015, its Financial Improvement Plan is focused on reducing costs, improving margins and aligning the Company's operations around a more focused core infusion business. Since the end of the third quarter 2015 the Company:

Substantially completed the previously announced targeted workforce reduction and remains on track to deliver the expected $19 million in annual cost savings in 2016;

Achieved the anticipated additional supply chain program initiatives that are expected to add $3 million in annual savings in 2016;

Effected the initiatives expected to reduce corporate costs by $5 million in 2016; and

Implemented cost reduction programs that are expected to reduce infusion field costs by $5 million in 2016. These cost reductions are in specific targeted areas that include improved nursing utilization and productivity, travel expense, office expense, and other variable cost categories.

Carter Pate, Chair of the Financial Improvement Plan Committee of the Board of Directors, said, "We made significant progress towards implementing our cost savings and financial improvement initiatives during the fourth quarter. We continue to believe in the strength of the Company's infusion services platform and the direction in which the business is heading."

Rick Smith, President and Chief Executive Officer of BioScrip, said, "Our preliminary results for the fourth quarter 2015 reflect increased patients serviced in the fourth quarter compared to the fourth quarter of 2014, continued progress in the successful execution of our cost reduction initiatives and enhanced focus on our operations. Our team is encouraged by our progress as we enter 2016. We are committed to realizing the benefits of the Financial Improvement Plan and creating value for our shareholders."

With the continued implementation of the Company's financial improvement programs, FTI Consulting's engagement has concluded and Scott Davido is no longer acting as chief implementation officer.

Preliminary Fourth Quarter 2015 Expectations

The Company also announced today certain unaudited preliminary fourth quarter 2015 financial results. The Company anticipates total patient census growth of approximately 4% in the fourth quarter of 2015 compared to the same period in 2014. The Company anticipates Core Therapy patient census growth of approximately 9% in the fourth quarter of 2015 compared to the same period in 2014.

Liquidity and Capital Resources

During the fourth quarter BioScrip generated increased cash collections sequentially compared to the third quarter. In the fourth quarter, the Company generated its highest quarterly infusion division cash collection total for 2015. In addition, during the fourth quarter the Company collected approximately $6.8 million on an account receivable balance from a former PBM vendor. The Company had retained this receivable, which was excluded from the sale of the PBM business.

As of December 31, 2015, the Company had reduced the amount of borrowings outstanding on its Revolving Line of Credit to $15 million compared to $30 million of borrowings outstanding as of September 30, 2015. The Company improved its cash flow in 2015 and expects to be operating cash flow positive in 2016. In addition, the Company expects to pay down more than $12 million of bank term debt in 2016 from operating cash flow.

Exploration of Strategic Alternatives

As previously announced, BioScrip is executing on its Financial Improvement Plan and, with the assistance of its financial advisor, is reviewing a range of strategic alternatives, which could include, among other options, a potential sale or merger of the Company. As noted previously, the exploration of strategic alternatives will not necessarily result in any changes to the Company's current business plan and Financial Improvement Plan or any transactions or agreements. The Company does not intend to disclose developments regarding the exploration of strategic alternatives unless and until a final decision is made.

BioScrip Fourth Quarter 2015 Results Call

The Company expects to announce the release date of its fourth quarter 2015 financial results within the next four weeks.

About BioScrip, Inc.

BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

http://www.nasdaq.com/press-release/bioscrip-provides-business-update-on-implementation-of-financial-improvement-plan-and-progress-to-20160119-00189

[willlbone]

Might be a Valeant Pharma connection.

[Wallst_junkie]

Not sure but I quitly rode it to $3 last month from $1.60 and looking to do it again. :)

[Lone Wolf]

Shooting out the gate. Wonder why?

$BIOS

[magness]

After hitting a higher low two days ago, think this may make the same move it made after hitting 52 week low on 8/14. Similar action.

[Lone Wolf]

Squeeze!!!!

[Enterprising Investor]

Good entry points are generally after expiration of a rights offering.

[Roy London]

bottom has been in for a month..its now in breakout mode on a daily cloud break..

[Faisamtrader]

$BIOS alerted at $1.77...

[Rick026]

Bottom is in! Reversal is coming!

[Enterprising Investor]

Rights offering was a failure.

Shareholders has the right to subscribe for up to 200,000 units, which would have raised a maximum of $20 million.

Only 10,822 units were subscribed. The offer raised a mere $1,082,200.

It will be interesting to see how many units, if any, the large holders purchased.

[Enterprising Investor]

BioScrip, Inc. Announces Expiration and Results of Rights Offering (7/28/15)

ELMSFORD, N.Y., July 28, 2015 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip") today announced the expiration of the subscription period for its previously announced rights offering of subscription rights to purchase units consisting of (1) Series A convertible preferred stock, (2) Class A warrants, each to purchase one share of common stock at a price of $5.17 per share, and (3) Class B warrants, each to purchase one share of common stock at a price of $6.45 per share.

The subscription period expired at 5:00 p.m., New York City time, on July 27, 2015. Based on results received from American Stock Transfer & Trust Company, LLC ("AST"), the subscription agent for the rights offering, stockholders exercised subscription rights to purchase 10,822 units, consisting of 10,822 shares of the Series A convertible preferred stock, 31,025 Class A warrants, and 31,025 Class B warrants, at a subscription price of $100.00 per unit. BioScrip estimates that it will receive approximately $1,082,200 in aggregate gross proceeds from the consummation of the rights offering.

Rights that were not properly exercised by 5:00 p.m., New York City time, on July 27, 2015, have expired and are no longer exercisable. The shares of Series A convertible preferred stock, Class A and Class B warrants will be distributed by AST by way of direct registration in book-entry form or through the facilities of The Depository Trust Company, as applicable, on or about July 31, 2015.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities.

About BioScrip, Inc.

BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion services from over 70 locations across 28 states.

https://oltx.fidelity.com/ftgw/fbc/oftop/portfolio#positions

[Tails]

Yes, that would do it. If I decide to get into this issue I may go that route.
Thanks.

[Enterprising Investor]

One subscription right for every 343.65 shares held.

http://www.sec.gov/Archives/edgar/data/1014739/000114420415039871/v413701_424b3.htm

[Enterprising Investor]

You could also review all Schedule 13-Ds.

Find the first Item 5 in the past that details historical cost and then add back all of the subsequent filings.

[Tails]

Thanks EI.
New to this issue and just trying to get a handle on it.
Seems likely that Gamco's cost is at least double current valuation.

[Enterprising Investor]

GAMCO completes Item 5 differently.

Most filers provide the total amount invested. However, it would be hard to keep up when buying and selling between different accounts.

It really does not matter how much was paid in the past. GAMCO will participate in this rights offering just like SEV last September.

[Tails]

Any info handy as to what Gamco's cost basis is?
Thanks...

[Enterprising Investor]

BioScrip, Inc. Announces Record Date for Rights Offering (6/18/15)

ELMSFORD, N.Y., June 18, 2015 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) (the "Company") today announced that its Board of Directors set the record date for the previously disclosed upcoming rights offering (the "Rights Offering") as of the close of business June 25, 2015 (the "Record Date"). The Company expects the Rights Offering will commence no later than June 30, 2015 and conclude by the end of July 2015. On the commencement date, or as soon as practicable thereafter, the Company will distribute the subscription rights, non-transferable subscription rights certificates and copies of the prospectus to stockholders of record as of 5:00 p.m. New York City time on the Record Date.

As previously announced, stockholders of record will receive, at no charge, their pro rata share of non-transferable subscription rights with respect to the outstanding shares of common stock owned by them on the Record Date, subject to rounding adjustment as contemplated by the terms of the Rights Offering. The subscription rights are for the purchase of units consisting up to an aggregate of (1) 200,000 shares of 8.5%/11.5% Series A convertible preferred stock, (2) 576,000 Class A warrants, each full warrant to purchase one share of the Company's common stock ("Common Stock") at a price of $5.17 per share, and (3) 576,000 Class B warrants, each full warrant to purchase one share of Common Stock at a price of $6.45 per share.

This press release is for informational purposes only. Additional details regarding the Rights Offering are included in the Company's Form S-3 filed with the Securities and Exchange Commission (the "SEC") on March 10, 2015, as amended on May 29, 2015 (File No. 333-202631), and the Company will be filing a final prospectus at the time the Rights Offering is commenced, which will contain final terms. The rights and securities offered for subscription thereunder may not be sold, nor may offers to buy be accepted, prior to the time such registration statement becomes effective. The Rights Offering is being made only pursuant to the prospectus and non-transferable subscription rights certificate, both of which are being distributed to holders of common stock and have been filed with the SEC as part of such registration statement.

The Company continues to evaluate market conditions and financing options that would improve its current liquidity profile and enhance its financial flexibility. This may include, but is not limited to, opportunities to raise additional funds through the issuance of various forms of equity and/or debt securities or other instruments, including additional rights offerings.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these rights offering securities, nor shall there be any sale of these rights offering securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A written prospectus for the Rights Offering, when available, may be obtained by contacting Georgeson Inc., 480 Washington Blvd., 26th Floor, Jersey City, NJ 07310, Tel: [phone].

About BioScrip, Inc.

BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion services from over 70 locations across 28 states.

http://www.prnewswire.com/news-releases/bioscrip-inc-announces-record-date-for-rights-offering-300101752.html

[Enterprising Investor]

GAMCO Investors, Inc owns 12,011,146 beneficial shares (6/08/15)

Controls 17.50 percent.

See Item 5 for a listing of beneficial owners.

http://www.sec.gov/Archives/edgar/data/807249/000080724915000124/bios_10.htm

[Enterprising Investor]

BIOS up 8 percent in pre-market trading (4/09/15)

[Enterprising Investor]

[From the Department of Corrections]

The earlier Schedule 13D detailed 9,388,901 shares, representing 13.68 percent.

http://www.sec.gov/Archives/edgar/data/807249/000080724915000046/bios_07.htm

[Enterprising Investor]

GAMCO Investors, Inc owns 10,399,401 beneficial shares (3/26/15)

Controls 15.15 percent.

See Item 5 for a listing of beneficial owners.

http://www.sec.gov/Archives/edgar/data/807249/000080724915000054/bios_08.htm

[Phaedrus77]

They own 10.4 million shares in total...15.15%. Looks like they bought another million shares (give or take) in the past 2 weeks.

[Enterprising Investor]

BioScrip, Inc. Amends Warrants (3/24/15)

Addendum to the Warrants

As part of the Transaction, the Company and the Investors entered into a Warrant Agreement on March 9, 2015 to memorialize the terms and conditions of the Warrants. On March 23, 2015, the Company entered into an Addendum to the Warrant Agreement with the Investors.

Pursuant to the Addendum, the Investors made an aggregate payment to the Company of $483,559 (the “Payment”) in exchange for a reduction in the exercise price of the Warrants in a corresponding per share amount to give effect to the Payment. As a result, the exercise price of the Class A Warrants was reduced to $5.17, and the exercise price of the Class B Warrants was reduced to $6.45. The Company and the Investors agreed to enter into the Addendum to ensure that the Transaction complied with NASDAQ Marketplace Rule 5635(d). All other terms of the Transaction remained the same. The Payment will be used by the Company for general corporate purposes.

Rights Offering

The Company previously announced its intention to conduct a registered rights offering to grant Company stockholders the right to purchase their pro rata share of a $20 million offering of the same securities that were offered to the Investors in the Transaction. If the Company decides to effect this rights offering, the warrants offered to the stockholders in that offering will contain the same exercise prices as set forth in the Addendum.

On March 10, 2015 the Company filed an initial registration statement for that potential rights offering with the Securities and Exchange Commission. The rights and securities offered for subscription thereunder may not be sold, nor may offers to buy be accepted, prior to the time such registration statement becomes effective.

http://www.sec.gov/Archives/edgar/data/1014739/000114420415018089/v405346_8k-a.htm

[gdog]

Cloud Gate Capital, LLC and Delaware Street Capital Master Fund, L.P. have sold off shares. DSC sold 1,503,757 shares on 3/10/15, while CCG sold 827,172 shares.
forgive my ignorance, are these hedge funds? and is this short covering?

[Enterprising Investor]

The Private Placement may have resulted in the desired effect.

Cloud Gate Capital, LLC and Delaware Street Capital Master Fund, L.P. have sold off shares. DSC sold 1,503,757 shares on 3/10/15, while CCG sold 827,172 shares.

http://www.sec.gov/Archives/edgar/data/1014739/000119312515087863/d887494dsc13da.htm

http://www.sec.gov/Archives/edgar/data/1014739/000119312515087886/d887510dsc13da.htm

I would not be surprised to see future filings detailing additional sales.

In any case, I bought shares yesterday at $3.55.

[Enterprising Investor]

Rights Offering:

Each whole subscription right will entitle holders of our common stock on the record date stock (excluding the holders of the PIPE Shares, who will not participate on any as-converted basis), to purchase one unit at a subscription price of $100.00 per unit. Each unit comprises one share of our convertible preferred stock, 2.88 Class A warrants and 2.88 Class B warrants. No fractional rights or units will be distributed or issued. The shares of convertible preferred stock will initially be convertible into shares of common stock at a conversion price of $5.17 per share, which was the conversion price of the convertible preferred stock we issued in the Private Placement, identical to the closing price of our common stock on the last full trading day prior to the completion of the Private Placement.

BIOS currently has 68,636,965 shares outstanding. Based on 200,000 units, it appears that shareholders will receive one right for every 343 shares held.

[Enterprising Investor]

Form S-3:

http://www.sec.gov/Archives/edgar/data/1014739/000114420415014927/v403949_s3.htm

[Enterprising Investor]

BioScrip Raises $62.5 million in Private Placement of Convertible Preferred Stock and Announces Plan for $20 million Rights Offering (3/09/15)

Appoints Christopher Shackelton to BioScrip Board of Directors

ELMSFORD, N.Y., March 9, 2015 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip") today announced the sale of $62.5 million in Series A Convertible Preferred Stock ("Preferred Stock") to Coliseum Capital Management, LLC ("Coliseum Capital") and affiliated funds. The Preferred Stock is convertible into 12,088,975 shares of BioScrip's common stock at a conversion price of $5.17 per share, which was the closing price of BioScrip's common stock on the NASDAQ Global Market on March 6, 2015. Dividends on the Preferred Stock will be payable quarterly at an annual rate of 8.5% if paid in cash or 11.5% if accrued. As part of the transaction, BioScrip issued to Coliseum Capital warrants for an aggregate of 3.6 million shares of BioScrip stock. Warrants for 1.8 million shares are exercisable at $5.295 per share and warrants for 1.8 million shares are exercisable at $6.596 per share.

In addition, BioScrip intends to conduct a registered rights offering to allow all of BioScrip's existing stockholders of record, on a date to be determined by the Board, the non-transferable right to purchase their pro rata share of $20.0 million of Preferred Stock and warrants on the same terms as the completed private placement to Coliseum Capital. Coliseum Capital and its affiliates will not participate in the rights offering. Additional details regarding the anticipated rights offering will be included in the Company's Form S-3, which it intends to file with the Securities and Exchange Commission.

The proceeds from the private placement will be used primarily to reduce BioScrip's outstanding indebtedness.

Christopher Shackelton, a Co-Founder and Managing Partner of Coliseum Capital, will join the BioScrip Board of Directors effective immediately.

Richard M. Smith, President and Chief Executive Officer of BioScrip, said, "We are pleased to announce this strategic investment by Coliseum Capital which we expect will enhance BioScrip's financial flexibility. We are excited to welcome Chris to our Board and believe his extensive experience in the healthcare services industry will bring added value to our Company."

Mr. Shackelton, said, "Coliseum is excited to be partnering with BioScrip. We believe strongly in the benefits of expanding the delivery of home-based healthcare, which start with improved patient care and outcomes, and extend to lower costs for payers. Specifically, we see significant value to the healthcare system from home-based infusion therapy. I am pleased to be joining BioScrip's Board and I look forward to working with the Company."

The closing of the private placement occurred today pursuant to a securities purchase agreement in connection with a financing transaction pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder. The securities that were sold in the completed private placement have not been registered under the Securities Act, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements.

The Company intends to file a registration statement with the Securities and Exchange Commission relating to the rights offering. The rights and securities offered for subscription thereunder may not be sold, nor may offers to buy be accepted, prior to the time such registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these rights offering securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cain Brothers & Company LLC served as BioScrip's financial advisor. Polsinelli PC is serving as legal advisor to BioScrip, and Paul Hastings LLP is serving as legal advisor to Coliseum Capital. Goodwin Procter LLP is serving as legal advisor to Cain Brothers.

About Mr. Shackelton
Christopher Shackelton has significant public company board experience, specifically within the healthcare services industry. He is currently Chairman of Providence Service Corp, a diversified healthcare holding company. He also serves on the board of LHC Group, a post-acute home nursing and hospice company. He was previously Chairman of Rural/Metro Corp, an emergency ambulance company. He is a Co-Founder and Managing Partner at Coliseum Capital Management, LLC. He received a bachelor's degree in Economics from Yale College.

About Coliseum Capital Management, LLC
Coliseum Capital is an investment firm founded in 2005 by Managing Partners Christopher Shackelton and Adam Gray, which focuses on long-term investments in both public and private companies. Coliseum directs capital behind strong management teams, with a willingness to work alongside companies to facilitate further value creation.

About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion and home care services from over 70 locations across 29 states.

http://www.prnewswire.com/news-releases/bioscrip-raises-625-million-in-private-placement-of-convertible-preferred-stock-and-announces-plan-for-20-million-rights-offering-300047294.html

[Enterprising Investor]

BioScrip Reports Fourth Quarter 2014 Financial Results (3/02/15)

ELMSFORD, N.Y., March 2, 2015 /PRNewswire/ -- BioScrip®, Inc. (NASDAQ: BIOS) (the "Company") today announced 2014 fourth quarter financial results. Fourth quarter revenue from continuing operations was $253.7 million and the net loss from continuing operations was $61.9 million, or $0.90 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.69.

Fourth Quarter Highlights

•Total revenue increased by $28.2 million, or 12.5%, as compared to the prior year period. Revenue from the Infusion Services segment increased to $239.5 million, reflecting 13.0% growth year-over-year, driven by organic revenue growth;

•Gross profit from continuing operations was $65.6 million, or 25.9% of revenue, as compared to $68.2 million, or 30.2% of revenue, in the prior year period;

•Adjusted EBITDA from continuing operations was a loss of $30.6 million, primarily reflecting incremental allowance for bad debt expense.

•The Company booked an incremental $31.7 million charge to bad debt, an increase of $29.2 million compared to the prior year period, bringing the total bad debt expense in 2014 to $79.6 million. The Company believes this charge appropriately reserves older account receivables;

•The Company implemented an annualized $15 million in previously identified cost savings projects and identified incremental gross savings of $9 million expected to be realized in 2015, for a total of $24 million of expected gross cost savings in the year. Net of investments and expenses to support double digit organic growth and continued improvement of cash collections, the Company anticipates realizing a total of $10 million in net cost savings in 2015;

•Cash flow from continuing operations was positive for the second consecutive sequential quarter at $2.0 million; and,

•As a result of the continued focus on cash collections, the Company has increased monthly average accounts receivable collections from $70.0 million in the first quarter of 2014 to $83.0 million in the fourth quarter of 2014.

"Fourth quarter and full year 2014 results reflect double digit organic revenue growth in our infusion business. We have taken a number of actions to align our cost structure and focus our resources in support of core infusion therapies, which we believe will continue to drive profitable growth and shareholder value. In addition, following an in-depth review of our bad debt reserve, we recorded a charge this quarter that we feel appropriately reserves older account receivables," said Rick Smith, President and Chief Executive Officer of BioScrip.

"As we head into 2015, we expect to continue to focus on double digit organic growth, operating cash flow generation and cost savings initiatives. We have confidence that our platform and our solid payor and hospital relationships will continue to drive profitable growth," concluded Mr. Smith.

Results of Operations

Fourth Quarter 2014 versus Fourth Quarter 2013
Revenue from continuing operations for the fourth quarter of 2014 totaled $253.7 million, compared to $225.5 million for the same period a year ago, an increase of $28.2 million or 12.5%. Infusion Services segment revenue was $239.5 million in the fourth quarter of 2014 as compared to $212.0 million for the same period in 2013. The 13.0% increase was driven primarily by continued strong organic growth.

Consolidated gross profit for the fourth quarter of 2014 was $65.6 million, or 25.9% of revenue, compared to $68.2 million, or 30.2% of revenue, for the fourth quarter of 2013. The decrease in gross profit dollars and margin percentage was primarily the result of a decrease in the PBM Services segment and the impact of therapy mix on the Infusion Services segment.

During the fourth quarter of 2014, on a consolidated basis, Adjusted EBITDA from continuing operations declined by $43.9 million to a loss of $30.6 million, compared to $13.3 million in the prior year period. Infusion Services segment Adjusted EBITDA was a loss of $18.3 million in the fourth quarter of 2014.

PBM Services segment revenue was $14.2 million for the fourth quarter of 2014, compared to $13.5 million for the prior year period. PBM Services segment Adjusted EBITDA was $1.6 million, or 11.2% of segment revenue, for the fourth quarter of 2014 compared to $1.7 million, or 12.7% of segment revenue, in the prior year quarter.

Interest expense in the fourth quarter of 2014 was $9.3 million compared to $8.0 million in the prior year period.

Income tax expense for continuing operations in the fourth quarter of 2014 was $2.9 million compared to an income tax expense of $2.6 million in the prior year period.

Net loss from continuing operations for the fourth quarter of 2014 was $61.9 million, or a loss of $0.90 per basic and diluted share, compared to a net loss of $15.6 million, or $0.23 per basic and diluted share, in the prior year period.

Twelve Months Ended 2014 versus Twelve Months Ended 2013
Revenue from continuing operations for the twelve months ended December 31, 2014 totaled $984.1 million, compared to $769.5 million for the same period a year ago. The 27.9% increase was driven primarily by organic growth in infusion therapies. Infusion Services segment revenue was $922.7 million for the twelve months ended December 31, 2014, compared to $696.9 million for the same period in 2013, a 32.4% increase.

Consolidated gross profit for the twelve months ended December 31, 2014, was $261.1 million, or 26.5% of revenue, compared to $243.6 million, or 31.7% of revenue, in the prior year. The net increase in gross profit was primarily due to organic growth. Consolidated gross profit margin percentage was primarily impacted by the PBM Services segment and the impact of therapy mix on the Infusion Services segment.

PBM Services segment revenue for the twelve months ended December 31, 2014 was $61.4 million, compared to $72.6 million for the prior year period.

For the twelve months ended December 31, 2014, on a consolidated basis, Adjusted EBITDA from continuing operations declined by $68.8 million to a loss of $23.0 million, compared to $45.7 million in the prior year period. Infusion Services segment Adjusted EBITDA was $6.5 million, or 0.7% of segment revenue, compared to $60.7 million, or 8.7% of segment revenue, in the prior year. On a pro-forma basis, Infusion Services segment Adjusted EBITDA was $62.8 million, compared to $60.7 million, in the prior year period.

On a pro-forma basis, consolidated Adjusted EBITDA from continuing operations was $39.3 million, which adjusts for the impact of non-recurring items that primarily include $56.3 million in Infusion Services pro-forma adjustments and $5.8 million of one-time accounting fees incurred during the fourth quarter of 2014.

Interest expense for the twelve months ended December 31, 2014 was $38.5 million compared to the $28.2 million in the prior year.

Income tax expense from continuing operations for the twelve months ended December 31, 2014 was $11.4 million, compared to an income tax expense of $2.5 million in 2013.

The net loss from continuing operations, net of taxes, for the twelve months ended December 31, 2014 was $143.4 million, or $2.09 per basic and diluted share, compared to a net loss of $57.0 million, or $0.89 per basic and diluted share, in the prior year.

Liquidity and Capital Resources
For the twelve months ended December 31, 2014, BioScrip used $24.6 million in net cash from continuing operating activities, compared to cash used of $46.0 million during the twelve months of 2013, a decrease of $21.4 million. The Company achieved positive cash flow from continuing operations during the last two quarters of 2014. As of December 31, 2014, the Company has $740,000 in cash and $423.8 million of outstanding debt. In addition, the Company had availability of $70.0 million on its $75.0 million revolving credit facility.

Conference Call and Presentation

BioScrip will host a conference call and live webcast to discuss its fourth quarter 2014 financial results on March 2, 2015 at 8:30 a.m. Eastern Time. Interested parties may participate by dialing 800-771-6917 (US), or 212-231-2919 (International) or accessing a link on the Company's website at www.bioscrip.com. The Company is also providing supplemental slides that will be posted prior to the conference call and will be accessible through the "Investor Relations" section of the BioScrip website at www.bioscrip.com.

A replay of the conference call will be available for two weeks after the call's completion by dialing 800-633-8284 (US) or 402-977-9140 (International) and entering conference call ID number 21762174. An audio webcast and archive will also be available for 30 days under the "Investor Relations" section of the Company's website.

About BioScrip, Inc.

BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion services from over 70 locations across 29 states.

http://www.prnewswire.com/news-releases/bioscrip-reports-fourth-quarter-2014-financial-results-300043373.html

[Enterprising Investor]

BioScrip Nominates Three New Independent Directors (2/09/15)

ELMSFORD, N.Y., Feb. 9, 2015 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) (the "Company") today announced that it will nominate David Golding, Michael Goldstein and R. Carter Pate for election to the BioScrip Board of Directors at the Company's 2015 Annual Meeting of Shareholders (the "Annual Meeting").

Messrs. Golding, Goldstein and Pate would replace Samuel P. Frieder, David R. Hubers and Gordon H. Woodward, who will not be standing for re-election at the Annual Meeting. Upon election the BioScrip Board will continue to be composed of nine directors, eight of whom are independent.

Richard M. Smith, President and Chief Executive Officer of BioScrip, said, "Our new independent director nominees each bring strong and relevant backgrounds, and will add valuable experience and perspective to the BioScrip Board. I would like to take the opportunity to thank Samuel, David, and Gordon for their service to BioScrip over the years and for their efforts in helping to position the Company as a leader in infusion services."

In connection with the nomination of Mr. Golding, BioScrip has entered into an agreement with DSC Advisors L.L.C. ("DSC") and Cloud Gate Capital LLC ("Cloud Gate"), which collectively own approximately 7.2% of the outstanding shares of BioScrip, under which Mr. Golding is authorized to attend all Board meetings as a non-voting observer to the BioScrip Board, effective immediately, and will serve on the Governance, Compliance and Nominating Committee of the Board upon election at the Annual Meeting.

Andrew Bluhm of DSC said, "We are pleased to have worked constructively with the Company to reach a mutually agreeable outcome. We believe Mr. Golding's deep operational experience in this industry will further position BioScrip to use its strong infusion services platform to achieve its growth potential while improving margins. We look forward to the appointment of a new CFO. We also believe that the significant financial, healthcare, and prior board experience of Mr. Goldstein and Mr. Pate will serve the Company well."

Under the agreement, DSC and Cloud Gate have withdrawn their nomination notice and agreed to vote their shares in favor of each of the BioScrip Board's nominees at the Annual Meeting. The full agreement will be filed in a Form 8-K with the Securities and Exchange Commission later today.

Caldwell Partners assisted BioScrip's Board in the director nominee search process. Polsinelli PC is serving as legal advisor to the Company.

About David Golding

David Golding has more than 30 years of healthcare industry experience within the home infusion and specialty pharmacy, hospital and retail sectors. He is the former Executive Vice President of Specialty Pharmacy at CVS/Caremark, where he was directly responsible for an $8 billion P&L, business strategy and pharmacy operations for a network of 75 pharmacies, sales and clinical development, while also participating as a key stakeholder in manufacturer relations and managed care contracting initiatives. He began his 25 year career at Caremark in its home infusion business and was promoted to numerous positions while becoming an expert in the pharmacy benefit management (PBM) business through ongoing joint initiatives across the CVS/Caremark organization. Since retiring from CVS/Caremark in 2011, he has consulted with national managed care organizations, specialty pharmacy providers, PBMs and other healthcare companies.

Most recently, Mr. Golding was on the Board of Directors for Salveo Specialty Pharmacy, a private-equity backed specialty pharmacy company, until it was sold to Catamaran in January of 2015. He is a registered pharmacist.

About Michael Goldstein

Michael Goldstein has decades of boardroom experience for both public companies and other organizations. He is a member of the Board and Chair of the Audit Committee at Teladoc, a leading virtual doctor organization, Pacific Sunwear, MedExpress, Sleepy's and Ri Happy. He also serves as a Board Member of Israel Discount Bank of New York and is an Advisory Board Member at Jefferies, Inc. He also acts as Chairman of the Northside Center for Child Development, is on the Board of Rosie's Theatre Kids and was previously Chairman of the 92nd Street Y. Mr. Goldstein was also previously Lead Director, Chairman of the Nominating and Governance Committee, and a member of the Audit and Mergers & Acquisitions committees at Medco Health Solutions, where he served until the sale of Medco to Express Scripts in 2012. He has also served as Chairman and Chief Executive Officer of Toys "R" Us Inc. and as Senior Executive Vice President – Operations and Finance of Lerner Stores Corporation. He was formerly a Partner at EY.

Mr. Goldstein was appointed by President George W. Bush to serve on the Advisory Committee for Trade Policy and Negotiations from 2003-2004 and has been honored by the A.L.S. Foundation, The Federation of Jewish Philanthropies, the NAACP, the Genetic Disease Foundation, among his numerous recognitions.

About R. Carter Pate

R. Carter Pate has more than 38 years of consulting and executive leadership experience. He is currently a strategic advisor to the Board of Directors of MV Transportation, Inc., and previously served as chief executive officer of MV until September 2014. Prior to that, Mr. Pate was the US and Global Managing Partner for the Healthcare and Government practices at PricewaterhouseCoopers, LLP. He was also a Founding Partner of Pate, Winters & Stone, Inc. a management and consulting services firm and formerly served as Interim President, CEO, and a member of the board of directors of Sun TV and Appliance, Inc. and CEO and Director of Sun Coast Industries, Inc. (NYSE). Mr. Pate is currently on the Board of the Dallas Regional Chamber and a member of the National Association of Corporate Directors. He has previously served on other boards of directors, including as Lead Director of Carmel Worldwide, MV Transportation, Inc., Board of Baylor Healthcare in Plano, TX, George Mason University Board of Visitors and Hunt Liquidating Trust.

He has received numerous certifications including Certified Public Accountant (CPA), Texas, Forensic Certified Public Accountant (FCPA) and Certified Government Financial Manager (CGFM-Yellow Book).

About BioScrip, Inc.

BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, facilities-based providers, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. BioScrip provides its infusion and home care services from over 70 locations across 29 states.

http://www.prnewswire.com/news-releases/bioscrip-nominates-three-new-independent-directors-300032681.html

[Enterprising Investor]

GAMCO Investors, Inc owns 7,290,847 beneficial shares (1/26/15)

Controls 10.62 percent.

See Item 5 for a listing of beneficial owners.

http://www.sec.gov/Archives/edgar/data/807249/000080724915000015/bios_05.htm

[Enterprising Investor]

Delaware Street Capital Advisors beneficially owns 3,215,789
shares (1/21/15)

Controls 4.7 percent.

The average cost paid is $6.23 per share.

http://www.sec.gov/Archives/edgar/data/1014739/000119312515017673/d856434dsc13da.htm

[Enterprising Investor]

Cloud Gate Capital, LLC beneficially owns 1,339,993 shares (12/30/14)

Controls 1.95 percent.

http://www.sec.gov/Archives/edgar/data/1014739/000119312514456144/d843615dsc13d.htm

[Enterprising Investor]

Delaware Street Capital Advisors beneficially owns 2,848,189 shares (12/30/14)

Controls 4.1 percent.

http://www.sec.gov/Archives/edgar/data/1014739/000119312514456149/d843635dsc13d.htm

[Enterprising Investor]

Activists Targeting BioScrip Will Nominate Directors (12/30/14)

BioScrip Inc could be facing a proxy fight from a pair of activist investors.

The pharmacy and home health-care company changed hands recently at $6.79, up 3 percent. The shares are down 18 percent in the past six months.

Cloud Gate Capital and Delaware Street Capital Advisors, acting as a group, separately disclosed a total 6.1 percent stake in the pharmacy and home health services company Tuesday.

Each of the two affiliated investors intend to nominate new directors for election at the company's 2015 annual meeting, typically held in the spring.

Cloud Gate's David Heller and Brian Newman, together with DCS's Andrew G. Bluhm said they've held "direct communications" with BioScrip's Chairman Myron Z. Holubiak and Chief Executive Richard M. Smith concerning the plan.

The investors said they may hold discussions with the company concerning its strategic direction, operations and other issues.

Holubiak has been a director since 2005 and was named chairman in 2012. Smith joined the company in 2009 as president and was named CEO in 2011.

The company has been unprofitable in each of the past five quarters with choppy revenue.

About a year ago, BioScrip agreed to pay $15 million to settle allegations that BioScrip received kickbacks from Novartis Pharmaceuticals Corp. to promote Novartis' drug Exjade through a patient education program.

http://www.benzinga.com/news/14/12/5110983/activists-targeting-bioscrip-will-nominate-directors

[TradeSmart.ai]

*Yawn* Wake me up when we finally hit $8.00 lol

[TradeSmart.ai]

Nice day today, let's see if it can continue next week.

$BIOS